Connect with us

Wellness

Science edges towards breakthrough in male contraception

Published

on

After decades of women carrying contraceptive responsibility, advancements in the development of male contraceptives could see products approved for use within the next few years, with the potential to shift the burden of birth control.

For all the freedoms that come with it, for decades, women have borne the brunt of the responsibility for birth control, subjecting themselves to painful medical procedures and hormonal side effects, all to avoid unwanted pregnancy.

There are significantly fewer options when it comes to contraception for men, who are limited to using condoms or, at the other end of the extreme, undergoing a vasectomy.

But the field is on the cusp of transformation, with new advancements in male contraceptives that could rebalance the burden of birth control and give men a more active role in family planning.

First FDA-approved hormonal contraceptive for men

Scientists at biotech company Contraline are behind two advanced-stage innovations taking different approaches to male contraception, both of which are currently progressing through clinical trials.

Its lead candidate, NES/T – a transdermal gel that combines nestorone and testosterone to suppress sperm production – is said to be the most advanced male contraceptive currently in development and is poised to become the first FDA-approved hormonal contraceptive for men.

Applied daily to the user’s shoulders, it systemically delivers the two exogenous hormones to reduce sperm count, while balancing the serum hormones, such as testosterone, of the patient to minimise side-effects.

A Phase 2b study on NES/T, led by the Population Council and the NICHD, on over 400 couples, most of whom used the gel for around 18 months, showed “encouraging efficacy in suppressing sperm levels to contraceptive thresholds, along with a favourable safety profile,” Kevin Eisenfrats, co-founder and CEO of Contraline, tells Femtech World.

“We believe NES/T will be transformational in getting men excited about using contraception.”

Full results from the trial are expected to be published later this year, and in July, Contraline announced its decision to exercise its exclusive option agreement to license NES/T from the Population Council.

A Phase 3 trial is expected to launch in 2026 to pave the way for regulatory approval within the next few years.

Eisenfrats described this as a “pivotal moment” not just for Contraline, but for the “future of contraception”.

“We’re proud to build on the decades of groundbreaking work by the Population Council and NICHD and carry this momentum into Phase 3 and beyond,” he said in a statement at the time.

“Long-acting, reversible birth control”

In the meantime, Contraline is also developing an alternative to the vasectomy in the form of ADAM, billed as the world’s first injectable hydrogel designed to provide long-lasting, non-hormonal, and reversible contraception for men.

Injected into the vas deferens, the same duct targeted during a vasectomy, the gel forms a “soft, flexible barrier” that blocks sperm rather than cutting or permanently sealing it. While NES/T works systemically and requires consistent application, ADAM is localised and takes a set-it-and-forget-it approach. Compared to hormonal methods, it simply blocks sperm in the vas, meaning the user won’t experience any systemic side effects.

Crucially, unlike a vasectomy, ADAM is not permanent, but is designed to last up to two years and be easily reversible.

The hydrogel degrades naturally after this time, mirroring the concept of how intrauterine devices (IUDs) are used in women. Contraline has also designed a ‘minimally invasive’ reversal procedure to remove the implant and restore fertility before its two-year lifespan, which has been tested in pre-clinical models and is set to be incorporated into upcoming trials.

The results from its first in-human clinical trial of ADAM, were published in April, demonstrating both safety and efficacy, with no treatment-related serious adverse events reported, and Contraline has now received full regulatory approval to initiate a Phase 2 (Early Feasibility) clinical study in Australia later this year.

While not intended to replace the role of condoms in protecting against STIs, ADAM could reduce dependence on hormonal birth control and is expected to have fewer side effects than female options such as IUDs.

“ADAM fills a major gap: it offers men a long-acting, reversible form of birth control that simply doesn’t exist today,” Eisenfrats says

“It also complements female contraception in couples who want to share responsibility. There is a strong chance that the ADAM procedure could have fewer side effects and, therefore, be more appealing than IUDs for women, especially given that most IUDs are hormonal.

Shifting the burden of responsibility

Beyond the medical potential of products like ADAM and NES/T, these developments in male contraceptives could pave the way for a cultural shift in how we think about contraception.

“ADAM opens the door for a fundamental shift in how we think about contraceptive responsibility,” says Eisenfrats.

“Historically, the burden has disproportionately fallen on women. This relieves some of the burden placed on women, while empowering men to be great partners and take an active role.

He adds: “Male contraception will also be an option for couples where the female can’t be on hormonal birth control. By enabling men to step forward with a long-acting, non-hormonal option, we help drive the larger goal of gender equity in family planning.”

Such significant shifts in societal attitudes take time, though, and for real change to happen, men will have to be willing to play a more active role in sharing the contraceptive load.

Contraline is keen to play a part in this, building a strategy around “open conversation, education and storytelling”.

“This means meeting people where they are, whether that’s online, in clinics, or through partnerships with healthcare providers,” he says.

“Our approach emphasises shared responsibility, not just a shift from one partner to another. It’s about creating a new narrative that contraception can and should be a mutual decision, and that men have a role to play in protecting their partner’s health and their own future.”

Promisingly, there has been “overwhelming interest” from men and their partners coming forward to participate in clinical trials, with over 19,000 currently on Contraline’s waiting list, Eisenfrats says. While in Australia, 1,500 men came forward to take part in a trial with only 25 places.

“The enthusiasm and demand we have seen from the patients and investigators involved in the trials have been unmistakable,” Eidenfrats adds.

“The world is ready for male birth control.”

Mental health

Women over 40 seeking raves for mental health benefits

Published

on

Women over 40 are seeking raves for mental and physical wellbeing, with a study suggesting the benefits go beyond nightlife.

The findings challenge the idea that nightlife and electronic dance music events are mainly for younger people.

Published in Psychology of Music, the study focused on the common misconception that nightlife is only for younger audiences.

Researchers surveyed 136 female clubbers aged 40 to 65 about their experiences at electronic dance music events.

The study, carried out at the University of Leeds in England, found women reported mental and physical wellbeing benefits from attending these events.

Seeing favourite DJs was the most common motivation, but many women also described dancing as a way to relieve stress and find emotional support.

The research found that 65.9 per cent of participants described attending a rave as “spiritual”, while 62.9 per cent said it offered an escape from everyday life.

A further 58.3 per cent said they felt like a different version of themselves in a club environment.

Nine in ten participants said they felt at home at electronic dance music events, with many pointing to a shared passion for music and the sense of community around it.

The study also suggested physical fitness played a role, with some women saying they had made clubbing part of their regular exercise routine.

However, the findings also highlighted challenges for older women in nightlife spaces.

One fifth of participants said they felt visibly out of place because of their age.

Nearly half reported unwanted physical contact, leading some to seek out different venues or attend only with friends.

Continue Reading

Wellness

WUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty

Published

on

This summer, WUKA and triple Olympian Hannah Miley MBE are bringing their Period-Positive Pool Party to London Aquatics Centre with one clear mission: to prove that periods should never keep anyone out of the water

At a time when 84 per cent of teenage girls in the UK say their interest in sport declines after starting their period – and nearly 70 per cent report skipping sports or swimming due to menstruation – WUKA’s immersive community event is tackling one of the most overlooked barriers to girls’ participation head-on.

WUKA’s Period-Positive Pool Party was created as a safe, inclusive space for teens to swim on their periods with confidence.

Following a series of sold-out events across the UK, including Eastleigh and Stonehaven in Hannah Miley’s hometown of Aberdeen, the London-based Olympic venue is a result of growing demand from teens and parents seeking supportive, stigma-free spaces to stay active during menstruation.

Why This Matters?

For many young people – particularly those who are not ready to use tampons due to age, comfort, cultural reasons, or parental guidance – swimming during their period can feel inaccessible.

WUKA’s period swimwear offers an alternative designed to provide comfort, coverage, and confidence, helping ensure that periods don’t mean sitting on the sidelines.

The new one-hour London takeover combines swimming, education, and empowerment in one of the UK’s most iconic sporting venues.

Breaking The Stigma While Making A Splash

So much more than a product event, WUKA’s Period-Positive Pool Party is a fully immersive experience featuring a DJ-approved summer playlist, inflatable pool installations, and professional underwater photography capturing barrier-free swimming moments. Every teen will also receive a curated £80 wellness goodie bag, including free WUKA swimwear.

But more than anything, they’re about freedom, confidence, and belonging, ensuring the confidence to swim, period, or not, continues long after they leave the water.

Hannah Miley MBE says: “Being an athlete taught me that your cycle isn’t a weakness, it’s just something to manage.

“Partnering with WUKA for this Pool Party is about showing young swimmers that with the right support and the right kit, they don’t have to press pause on their lives or their sport because of their period.”

WUKA Founder Ruby Raut says: “This is about more than a pool party – it’s about changing what inclusion in sport actually looks like.

“Too many girls step back from swimming and physical activity because of period stigma or lack of options.

“Through community-led events like this, we’re breaking barriers, building confidence, and making sure no one feels excluded from sport because of their cycle.”

Saturday 30th May 2026 | 5–6pm | London Aquatics Centre

Want to join the pool party? Follow this link to buy your tickets

Continue Reading

Pregnancy

App tracks heart risk after high-risk pregnancies

Published

on

A recent study developed a new “digital companion” to support the prevention and follow-up of maternal cardiovascular risk in women with pregnancy complications.

Cardiovascular disease, or CVD, is the leading cause of premature death and illness in women, yet sex-specific causes remain understudied and women are underrepresented in research.

Pregnancy complications, including hypertensive disorders of pregnancy, or HDP, and gestational diabetes mellitus, or GDM, are strong predictors of future CVD, with pregnancy itself acting as a natural stress test.

Despite CVD accounting for 35 per cent of female deaths worldwide in 2019, systematic postpartum prevention remains limited in practice and incidence continues to rise.

Myocardial infarction, commonly known as heart attack, and stroke are the main fatal CVD events in women. Up to one-third of women develop hypertension within a decade after HDP, especially as maternal age rises.

Obstetric guidelines have historically lacked clarity on early CVD prevention after HDP and GDM, often relying on expert consensus rather than evidence.

Some cardiology guidelines now recommend personalised approaches, such as periodic hypertension and diabetes screening. Norwegian guidelines recommend cardiovascular risk evaluation at three months and one year postpartum, but adherence in practice is uncertain.

Effective risk reduction requires intervention before middle age. The immediate postpartum period following HDP or GDM is a critical window for early detection and intervention, offering an opportunity to engage women in cardiovascular health management, particularly as pregnancy can encourage long-term lifestyle awareness.

Electronic health, or eHealth, refers to the use of digital technologies and electronic communication tools to support healthcare services, medical information management and related health activities.

Systematic, eHealth-supported postpartum prevention can improve maternal health literacy and long-term cardiovascular outcomes.

However, there is a significant gap in targeted, eHealth-based postpartum interventions for cardiovascular risk management after HDP and GDM, despite strong patient demand and international calls for coordinated digital health strategies.

Home blood pressure monitoring shows promise, but broader digital support remains limited.

A cardiovascular postpartum follow-up programme was created as a mobile app based on Norwegian and international guidelines.

The MumCare app was developed through co-creation involving users, stakeholders and clinical experts. Five qualitative interviews and 10 user testing sessions informed improvements.

This study primarily analysed the iterative co-creation process used to develop the app, rather than evaluating clinical outcomes.

The MumCare project team in Oslo included an IT expert, obstetricians, a midwife, a GP, two sociologists and two cardiologists, all with relevant experience in eHealth and women’s health. A medical student with technological and medical expertise also helped turn ideas into app features for young women.

User representatives from two national patient associations contributed to information, recruitment, design and testing of the MumCare app.

Both associations provided user perspectives and took part in interviews and app testing. Additional users with HDP or GDM at Oslo University Hospital were also involved throughout the co-creation process.

The app’s digital infrastructure prioritises security and privacy, using encryption, de-identification and two-factor authentication.

User data is stored securely on the app and, for research purposes and with consent, on a dedicated University of Oslo server in line with GDPR and Norwegian regulations.

A linear Stage-Gate model structured the co-creation process, dividing it into phases with quality checkpoints reviewed in project meetings.

This approach balanced internal development with external user feedback, helping ensure the app is evidence-based, technically robust and user-centred.

The MumCare app guides postpartum women through tracking blood pressure, weight, physical activity and lab results, and provides personalised feedback to support self-management, mainly during the first postpartum year.

It also includes educational resources such as videos and guideline-based information to support understanding and engagement.

The app is also designed to support the transition from specialist pregnancy care to long-term follow-up with general practitioners.

It is described as a “digital companion” or health coach and does not replace clinical diagnosis or function as a medical device.

The co-creation process followed four phases focused on technical and procedural development.

In phase 1, input from expert organisations and user representatives established the app’s technical foundation.

It also reminds users of the one-year postpartum follow-up with their GP, a key time to assess risk factors and future care needs.

User organisation representatives gave feedback in phase 1, directly guiding content and feature development.

Phase 2 interviews confirmed that users want to monitor cardiovascular risk factors after HDP and GDM.

The analysis highlighted three themes: self-care strategies and uncertainties about hypertension, the need for accessible health information, and a more personalised approach to blood pressure monitoring in the app.

Concerns were also raised that frequent monitoring or app use could increase stress or create a sense of burden.

In phase 3, the app’s design and features were revised in response to feedback to improve usability and make sure they met users’ needs.

These changes led to a more intuitive and supportive interface for women during and after pregnancy.

Phase 4 involved building a prototype based on the updated designs, followed by further refinements after testing by the project team and users. Initial pilot testing with a small number of users suggested the app met its objectives and functioned as intended.

The MumCare app was co-created with input from experts, user organisations and patients over four phases.

Early expert and organisational contributions helped define the app’s goals, while ongoing feedback from patients helped ensure the design and content reflected users’ real needs.

This collaborative approach resulted in an app tailored to support women with pregnancy complications.

The MumCare app is currently being evaluated in a randomised controlled clinical trial that began in June 2024, with results needed to determine whether it improves long-term cardiovascular outcomes.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.